fmdog44
Well-known Member
- Location
- Houston, Texas
This is from an article in the latest Bloomberg Businessweek Magazine June 21. Aducanumab has been approved by the Food & Drug Administration.
"...it may be only minimally effective if it works at all." The evidence from the clinical trials that the drug reduces Alzheimer's is incomplete... All of which makes the announcement this month perplexing and wrong. Biogen INC. plans to price the drug at $56,000 per year for the average patient, it also stands to cost Medicare and other insurers a bundle."
"The agency (FDA) did not deny that the clinical trial evidence was poor. It simply ignored the problem and used different reasoning to grant the drug "accelerated approval."
Despite all the shay stuff surrounding the drug, the testing, the approval and the company Biogen will sell the drug Aducanumab under the name Aduhelm. So despite it being unproven and super expensive Medicare is poised to do it. Under current law allow pharmaceutical to charge and collect high prices until a merely promising drug is proved to be of no use.
"...it may be only minimally effective if it works at all." The evidence from the clinical trials that the drug reduces Alzheimer's is incomplete... All of which makes the announcement this month perplexing and wrong. Biogen INC. plans to price the drug at $56,000 per year for the average patient, it also stands to cost Medicare and other insurers a bundle."
"The agency (FDA) did not deny that the clinical trial evidence was poor. It simply ignored the problem and used different reasoning to grant the drug "accelerated approval."
Despite all the shay stuff surrounding the drug, the testing, the approval and the company Biogen will sell the drug Aducanumab under the name Aduhelm. So despite it being unproven and super expensive Medicare is poised to do it. Under current law allow pharmaceutical to charge and collect high prices until a merely promising drug is proved to be of no use.